Short Interest in InterCure Ltd. (NASDAQ:INCR) Grows By 19.8%

InterCure Ltd. (NASDAQ:INCR) was the target of a large increase in short interest in February. As of February 13th, there was short interest totaling 4,894 shares, an increase of 19.8% from the January 29th total of 4,086 shares. Based on an average trading volume of 40,557 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 40,557 shares, the short-interest ratio is presently 0.1 days.

InterCure Price Performance

Shares of NASDAQ INCR opened at $0.85 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.85 and a debt-to-equity ratio of 0.27. InterCure has a 1-year low of $0.68 and a 1-year high of $1.77. The business’s fifty day moving average price is $0.92 and its two-hundred day moving average price is $1.28.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of InterCure in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, InterCure presently has an average rating of “Sell”.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.